Elekta AB Class B EKTAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $6.45
- Day Range
- $6.25–6.25
- 52-Week Range
- $6.13–8.40
- Bid/Ask
- $6.50 / $7.10
- Market Cap
- $2.39 Bil
- Volume/Avg
- 6,061 / 26,173
Key Statistics
- Price/Earnings (Normalized)
- 18.13
- Price/Sales
- 1.40
- Dividend Yield (Trailing)
- 3.69%
- Dividend Yield (Forward)
- 3.72%
- Total Yield
- 3.69%
Company Profile
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,000 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 31%; Europe, the Middle East, and Africa accounting for 35%; and the Asia-Pacific contributing the remainder.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Mid Core
- Total Number of Employees
- 4,566
- Website
- https://www.elekta.com
Competitors
Valuation
|
Metric
|
EKTAF
|
SHL
|
BDX
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.13 | 24.04 | 18.67 |
Price/Book Value | 2.41 | 3.18 | 2.66 |
Price/Sales | 1.40 | 2.62 | 3.51 |
Price/Cash Flow | 9.75 | 20.61 | 18.92 |
Price/Earnings
EKTAF
SHL
BDX
Financial Strength
|
Metric
|
EKTAF
|
SHL
|
BDX
|
|---|---|---|---|
Quick Ratio | 0.74 | 0.79 | 1.20 |
Current Ratio | 0.99 | 1.27 | 1.85 |
Interest Coverage | 5.15 | 6.36 | 4.20 |
Quick Ratio
EKTAF
SHL
BDX
Profitability
|
Metric
|
EKTAF
|
SHL
|
BDX
|
|---|---|---|---|
Return on Assets (Normalized) | 3.75% | 4.04% | 3.65% |
Return on Equity (Normalized) | 11.19% | 10.35% | 7.60% |
Return on Invested Capital (Normalized) | 8.20% | 11.27% | 5.30% |
Return on Assets
EKTAF
SHL
BDX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Lshpnvyz | Cwwlp | $196.0 Bil | |||
| Stryker Corp
SYK
| Zrnnpjxjx | Cdrtm | $133.8 Bil | |||
| Boston Scientific Corp
BSX
| Pzzytqcb | Hnmswt | $124.5 Bil | |||
| Medtronic PLC
MDT
| Pzbrzdlmc | Yftnj | $113.2 Bil | |||
| Edwards Lifesciences Corp
EW
| Vdrzhfpgw | Yfrqqjn | $39.5 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Ddc | Rvgx | $30.2 Bil | |||
| DexCom Inc
DXCM
| Nfdwnqvp | Fmp | $27.3 Bil | |||
| Steris PLC
STE
| Bgrkgnw | Vmymzt | $22.8 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Pwydtvksbw | Yqdxm | $21.3 Bil | |||
| Insulet Corp
PODD
| Rtgwknzmm | Dgdfyql | $16.1 Bil |
United States